scholarly journals Role of diabetes mellitus on the recurrence rate of hepatocellular carcinomas after radiofrequency ablation in chronic hepatitis C patients

2015 ◽  
Vol 1 (1) ◽  
pp. 24
Author(s):  
MohamedAbd El-Raouf Tawfik ◽  
Abd AllahAhmed El-Sawy
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Radiofrequency Ablation ◽  
Chronic Hepatitis C ◽  
Recurrence Rate ◽  
Hepatocellular Carcinomas ◽  
Chronic Hepatitis C Patients

scholarly journals Association of TM6SF2 rs58542926 with Hepatic and Extrahepatic Alterations in Chronic Hepatitis C Patients

2021 ◽  
Author(s):  
Mohi I. Mohammed Abdul ◽  
Adriana Vitiello ◽  
Hanieh Ghassabian ◽  
Heba M. Eltahir ◽  
Elham Ahmed Hassan ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Hepatitis C ◽  
Biochemical Analysis ◽  
Complete Blood Count ◽  
Minor Allele ◽  
Chronic Hepatitis C Patients ◽  
Severe Fibrosis

Abstract Human genetic variants play major roles in predicting and prognosis of several diseases. The effect of rs58542926 variant in transmembrane 6 superfamily member 2 (TM6SF2) gene on liver fibrosis among patients with chronic hepatitis C (CHC) is still debatable. The aim of this study is to investigate the possible effects of this variant in CHC patients. The study comprised 351 subjects: 250 CHC patients with different fibrosis stages (F0-F4) and 101 healthy volunteers. TM6SF2 (rs58542926) genotype was determined for all subjects. Blood samples were collected for complete blood count and biochemical analysis and cohort subjects were genotyped for the variant TM6SF2 rs58542926. Fibrosis staging was performed using Fibrotest and Fibroscan standard tests. The presence of the minor allele was significantly associated with severe liver fibrosis, as well as thrombocytopenia as an extrahepatic alteration. In addition, there was a significant association between the minor allele and lower thrombopoietin levels. The association of TM6SF2 genotype with thrombocytopenia was explored by measuring plasma thrombopoietin (TPO) levels for CHC patients. The results showed an association with extrahepatic alteration (thrombocytopenia) through its effect on plasma TPO level, and consequently on platelets production, which raises questions about the role of this variant in HCV treatment outcome. In conclusion, the occurrence of the minor allele of the variant rs58542926 can be linked to severe fibrosis stages as well as thrombocytopenia, enabling this variant to be used as a diagnostic pharmacogenetic marker for predicting the risk of fibrosis onset in CHC patients.

scholarly journals Role of anti-mutated citrullinated vimentin antibodies in chronic hepatitis C patients and its relation to HCV associated arthritis

2017 ◽  
Vol 39 (3) ◽  
pp. 175-178 ◽  
Author(s):  
Shahira El Fedawy ◽  
Hala Ghareeb ◽  
Neama Lotfy ◽  
Noran Osama El-Azizi ◽  
Asmaa Mahmoud
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Citrullinated Vimentin ◽  
Chronic Hepatitis C Patients

scholarly journals The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
A. Sirinawasatien ◽  
T. Techasirioangkun
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Hepatic Steatosis ◽  
Chronic Hepatitis C ◽  
Liver Stiffness ◽  
Controlled Attenuation Parameter ◽  
Attenuation Parameter ◽  
The Mean ◽  
Chronic Hepatitis C Patients

Aims. To describe the prevalence of hepatic steatosis using a controlled attenuation parameter (CAP) and to identify the determinants associated with steatosis in Thai chronic hepatitis C patients. Patients and Methods. An observational study was conducted among consecutive chronic hepatitis C patients who underwent vibration-controlled transient elastography (VCTE, FibroScan®) with CAP and followed up at Rajavithi Hospital, Bangkok, Thailand, between June 2018 and May 2019. Hepatic steatosis (i.e., steatosis grades S1-3) was defined by the CAP cutoff value of ≥248 (dB/m). VCTE with CAP assessments and medical records were retrospectively reviewed, and the prevalence and determinants of hepatic steatosis were analyzed. Results. A total of 197 eligible patients, of whom 127 (64.5%) were male, were included. The mean age was 54.52 years (SD 9.49 years), and 41.1% of subjects had a body mass   index ≥ 25 . The prevalence of hepatic steatosis was 26.9%. The mean liver stiffness measurement (LSM) was 21.50 kPa (SD 15.58 kPa), and 61.9% of the study population had cirrhosis, which was defined as LSM ≥ 12.5  kPa. Genotype (GT) 3 was predominant at 40.1%, followed by GT1 at 38.1% and GT6 at 21.8%. The median serum hepatitis C virus viral load was 1,100,000 IU/mL (range 5,824-20,436,840). The significant determinants of hepatic steatosis were obesity (aOR 8.58 (95% CI: 3.41-21.54)) and diabetes mellitus (aOR 3.30 (95% CI: 1.24-8.78)). Conclusion. A large proportion of these Thai chronic hepatitis C patients (26.9%) had hepatic steatosis, which was strongly associated with host metabolic factors, e.g., obesity ( BMI ≥ 25 ) and diabetes mellitus. These cofactors contributed to the progression of liver disease to cirrhosis and required concurrent management with antiviral therapy.

Sign in / Sign up

Export Citation Format

Share Document